Publisher Correction: Anti-inflammatory and anti-fibrotic effects of intravenous adipose-derived stem cell transplantation in a mouse model of bleomycin-induced interstitial pneumonia (Scientific Reports, (2017), 7, 1, (14608), 10.1038/s41598-017-15022-3);Anti-inflammatory and anti-fibrotic effects of intravenous adipose-derived stem cell transplantation in a mouse model of bleomycin-induced interstitial pneumonia

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Kotani, Takuya ^a   Masutani, Ryota ^a   Suzuka, Takayasu ^a   Oda, Katsuhiro ^a   Makino, Shigeki ^a   Ii, Masaaki ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85032791197     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-17991-x     Document Type: Erratum

References (42)

1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161, 646-664 (2000).
2. Kotani, T. et al. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol 35, 254-259 (2008).
3. King, T. E. Jr et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370, 2083-2092 (2014).
4. Richeldi, L. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370, 2071-2082 (2014).
5. Murphy, M. B., Moncivais, K. & Caplan, A. I. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med 15, e54 (2013).
6. Baer, P. C. Adipose-derived mesenchymal stromal/stem cells: An update on their phenotype in vivo and in vitro. World J Stem Cells 26, 256-265 (2014).
7. Caruso, M., Evangelista, M. & Parolini, O. Human term placental cells: phenotype, properties and new avenues in regenerative medicine. Int J Mol Cell Med 1, 64-74 (2012).
8. Taha, M. F. & Hedayati, V. Isolation, identification and multipotential differentiation of mouse adipose tissue-derived stem cells. Tissue Cell 42, 211-216 (2010).
9. Zuk, P. A. et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7, 211-228 (2001).
10. Weiss, D. J. Stem cells, cell therapies, and bioengineering in lung biology and diseases. Comprehensive review of the recent literature 2010-2012. Ann Am Thorac Soc 10, S45-S97 (2013).
11. Weiss, D. J. & Ortiz, L. A. Cell therapy trials for lung diseases: progress and cautions. Am J Respir Crit Care Med 188, 123-125 (2013).
12. McNulty, K. & Janes, S. M. Stem cells and pulmonary fibrosis: cause or cure? Proc Am Thorac Soc 9, 164-171 (2012).
13. Lalu, M. M. et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One 7, e47559 (2012).
14. Ortiz, L. A. et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 100, 8407-8411 (2003).
15. Rojas, M. et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 33, 145-152 (2005).
16. Zhao, F. et al. Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats. Transplant Proc 40, 1700-1705 (2008).
17. Kumamoto, M., Nishiwaki, T., Matsuo, N., Kimura, H. & Matsushima, K. Minimally cultured bone marrow mesenchymal stem cells ameliorate fibrotic lung injury. Eur Respir J 34, 740-748 (2009).
18. Lee, S. H. et al. Modulation of cytokine and nitric oxide by mesenchymal stem cell transfer in lung injury/fibrosis. Respir Res 11, 16 (2010).
19. Aguilar, S. et al. Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS One 4, e8013 (2009).
20. Moodley, Y. et al. Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. Am J Pathol 175, 303-313 (2009).
21. Saito, S. et al. Mesenchymal stem cells stably transduced with a dominant-negative inhibitor of CCL2 greatly attenuate bleomycininduced lung damage. Am J Pathol 179, 1088-1094 (2011).
22. Lim, R. et al. Human mesenchymal stem cells reduce lung injury in immunocompromised mice but not in immunocompetent mice. Respiration 85, 332-341 (2013).
23. De Ugarte, D. A. et al. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs 174, 101-109 (2003).
24. Cyranoski, D. Chinese genomics giant BGI plots commercial path. Nat Biotechnol 30, 1159-1160 (2012).
25. Grégoire, C. et al. Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases. Aliment Pharmacol Ther 45, 205-221 (2017).
26. Furuhashi, K. et al. Serum-starved adipose-derived stromal cells ameliorate crescentic GN by promoting immunoregulatory macrophages. J Am Soc Nephrol 24, 587-603 (2013).
27. Lee, S. H. et al. The effect of adipose stem cell therapy on pulmonary fibrosis induced by repetitive intratracheal bleomycin in mice. Exp Lung Res 40, 117-125 (2014).
28. Tashiro, J. et al. Therapeutic benefits of young, but not old, adipose-derived mesenchymal stem cells in a chronic mouse model of bleomycin-induced pulmonary fibrosis. Transl Res 166, 554-567 (2015).
29. Rathinasabapathy, A. et al. Therapeutic potential of adipose stem cell-derived conditioned medium against pulmonary hypertension and lung fibrosis. Br J Pharmacol 173, 2859-2879 (2016).
30. Harrison, J. H. Jr & Lazo, J. S. High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis. J Pharmacol Exp Ther 243, 1185-1194 (1987).
31. Nagata, H. et al. Cardiac adipose-derived stem cells exhibit high differentiation potential to cardiovascular cells in C57BL/6 mice. Stem Cells Transl Med 5, 141-151 (2016).
32. Hübner, R. H. et al. Standardized quantification of pulmonary fibrosis in histological samples. Biotechniques 44, 507-511 (2008).
33. Schweitzer, K. S. et al. Adipose stem cell treatment in mice attenuates lung and systemic injury induced by cigarette smoking. Am J Respir Crit Care Med 183, 215-225 (2011).
34. Maggini, J. et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One 5, e9252 (2010).
35. Anderson, P. et al. Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsis. Gut 62, 1131-1141 (2013).
36. Yousefi, F., Ebtekar, M., Soudi, S., Soleimani, M. & Hashemi, S. M. In vivo immunomodulatory effects of adipose-derived mesenchymal stem cells conditioned medium in experimental autoimmune encephalomyelitis. Immunol Lett 172, 94-105 (2016).
37. Xie, J. et al. Human adipose-derived stem cells suppress elastase-induced murine abdominal aortic inflammation and aneurysm expansion through paracrine factors. Cell Transplant 26, 173-179 (2017).
38. Cho, K. S. et al. Prostaglandin E2 and transforming growth factor-? play a critical role in suppression of allergic airway inflammation by adipose-derived stem cells. PLoS One 10, e0131813 (2015).
39. Cho, K. S. et al. Indoleamine 2,3-dioxygenase is not a pivotal regulator responsible for suppressing allergic airway inflammation through adipose-derived stem cells. PLoS One 11, e0165661 (2016).
40. Tatsumi, K. et al. Tissue factor triggers procoagulation in transplanted mesenchymal stem cells leading to thromboembolism. Biochem Biophys Res Commun 431, 203-209 (2013).
41. Uji, M., Nakada, A. & Nakamura, T. Intravenous administration of adipose-derived stromal cells does not ameliorate bleomycininduced lung injury in rats. Open J Regen Med 2, 39-45 (2013).
42. Cabral, R. M. et al. Cell therapy for fibrotic interstitial pulmonary disease: experimental study. Microsc Res Tech 74, 957-962 (2011).